Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure
暂无分享,去创建一个
[1] H. Mano,et al. Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines , 2007, Leukemia.
[2] S. Bates,et al. ABCG2: determining its relevance in clinical drug resistance , 2007, Cancer and Metastasis Reviews.
[3] A. Calcagno,et al. Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor , 2006, Molecular Cancer Therapeutics.
[4] D. Bowtell,et al. The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study , 2006, British Journal of Cancer.
[5] Erik Andries,et al. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. , 2006, Blood.
[6] A. Rademaker,et al. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. , 2006, The Journal of investigative dermatology.
[7] Suneet Shukla,et al. The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. , 2006, Biochemistry.
[8] T. Litman,et al. Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. , 2006, Cancer letters.
[9] T. Murakami,et al. Expression and function of efflux drug transporters in the intestine. , 2006, Pharmacology & therapeutics.
[10] R. Fanin,et al. The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. , 2006, Haematologica.
[11] R. Campbell,et al. The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts , 2005 .
[12] J. Schuetz,et al. Function-dependent Conformational Changes of the ABCG2 Multidrug Transporter Modify Its Interaction with a Monoclonal Antibody on the Cell Surface* , 2005, Journal of Biological Chemistry.
[13] B. Uggla,et al. BCRP mRNA expression v. clinical outcome in 40 adult AML patients. , 2005, Leukemia research.
[14] O. Legrand,et al. Breast Cancer Resistance Protein and P-Glycoprotein in 149 Adult Acute Myeloid Leukemias , 2004, Clinical Cancer Research.
[15] S. Ambudkar,et al. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. , 2004, Biochemical pharmacology.
[16] H. Kantarjian,et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. , 2004, Blood.
[17] Jeffrey W. Clark,et al. A Phase I Trial of Daily Oral 4′-N-Benzoyl-Staurosporine in Combination with Protracted Continuous Infusion 5-Fluorouracil in Patients with Advanced Solid Malignancies , 2004, Investigational New Drugs.
[18] S. Bates,et al. Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition , 2004, Cancer Research.
[19] S. Novello,et al. Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] M. Ratain,et al. Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor , 2004, Investigational New Drugs.
[21] S. Bates,et al. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity , 2003, British Journal of Cancer.
[22] S. A. Watkins,et al. Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors. , 2003, Bioorganic & medicinal chemistry letters.
[23] Hong Zhang,et al. The FASEB Journal express article 10.1096/fj.02-1131fje. Published online September 4, 2003. Expression and functional characterization of ABCG2 in brain endothelial cells and vessels , 2022 .
[24] L. Doyle,et al. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) , 2003, Oncogene.
[25] S. Nishimura,et al. ABCG2 confers resistance to indolocarbazole compounds by ATP-dependent transport. , 2002, Biochemical and biophysical research communications.
[26] I. Catalá,et al. Frequent expression of the multi‐drug resistance‐associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP‐21 monoclonal antibody in paraffin‐embedded material , 2002, The Journal of pathology.
[27] A. Eastman,et al. A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01. , 2002, Molecular cancer therapeutics.
[28] J. Schellens,et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Doriano Fabbro,et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. , 2002, Cancer cell.
[30] P. Cohen. Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.
[31] B. Torok-Storb,et al. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. , 2002, Blood.
[32] M. Kazanietz,et al. Protein kinase C isozymes, novel phorbol ester receptors and cancer chemotherapy. , 2001, Current pharmaceutical design.
[33] H. Nakauchi,et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype , 2001, Nature Medicine.
[34] T. Litman,et al. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. , 2001, Biochemical and biophysical research communications.
[35] M. J. van de Vijver,et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. , 2001, Cancer research.
[36] H. Kotani,et al. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. , 2001, Cancer research.
[37] L. Doyle,et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. , 2001, Biochemical and biophysical research communications.
[38] T. Litman,et al. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[39] J. Schellens,et al. Transport of Topoisomerase I Inhibitors by the Breast Cancer Resistance Protein: Potential Clinical Implications , 2000, Annals of the New York Academy of Sciences.
[40] J. Schellens,et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. , 1999, Cancer research.
[41] O. Legrand,et al. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. , 1999, Blood.
[42] L. Drew,et al. The bisindolylmaleimide protein kinase C inhibitor, Ro 32-2241, reverses multidrug resistance in KB tumour cells , 1999, Cancer Chemotherapy and Pharmacology.
[43] S. Ambudkar. Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells. , 1998, Methods in enzymology.
[44] J. Sedlák,et al. Protein kinase inhibitor-induced alterations of drug uptake, cell cycle and surface antigen expression in human multidrug-resistant (Pgp and MRP) promyelocytic leukemia HL-60 cells. , 1997, Leukemia research.
[45] I. Fidler,et al. Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation. , 1997, Biochemical pharmacology.
[46] H. Grunicke,et al. Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance. , 1996, British Journal of Cancer.
[47] T. Gant,et al. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells. , 1996, British Journal of Cancer.
[48] C. Schächtele,et al. The specific bisindolylmaleimide PKC-inhibitor GF 109203X efficiently modulates MRP-associated multiple drug resistance. , 1995, Biochemical and biophysical research communications.